Oxytocin during myomectomy: a randomized study

Eur J Obstet Gynecol Reprod Biol. 2005 Feb 1;118(2):235-8. doi: 10.1016/j.ejogrb.2004.06.032.

Abstract

Objective: To evaluate the influence of oxytocin on peroperative blood loss during myomectomy.

Study design: From October 1998 to May 2002, 94 patients requiring surgical myomectomy by laparotomy or by the vaginal approach were enrolled in a randomized double blind study. Patients were randomized to two groups. In the first group (47 patients) oxytocin was administered during myomectomy and in the second group (47 patients) a placebo was used. The main outcome measures were peroperative blood loss and rates of blood transfusion and autotransfusion.

Results: Peroperative blood loss was no different between the oxytocin group and the placebo group (508 +/- 558 ml versus 451 +/- 336 ml; P=0.55). Rates of autotransfusion and blood transfusion were also similar in both groups.

Conclusion: Administration of oxytocin during myomectomy did not reduce peroperative blood loss in our study. The benefits of using oxytocin to prevent hemorrhage during myomectomy seem to be limited.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Blood Loss, Surgical / prevention & control*
  • Blood Transfusion
  • Double-Blind Method
  • Female
  • Hemoglobins / analysis
  • Humans
  • Leiomyoma / surgery*
  • Middle Aged
  • Oxytocin / administration & dosage*
  • Placebos
  • Uterine Neoplasms / surgery*

Substances

  • Hemoglobins
  • Placebos
  • Oxytocin